GSK (LON:GSK) Rating Reiterated by Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reiterated by investment analysts at Jefferies Financial Group in a research report issued to clients and investors on Thursday, Marketbeat reports. They presently have a GBX 2,100 ($26.64) price objective on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 37.30% from the company’s current price.

A number of other research analysts also recently commented on GSK. Barclays restated an “equal weight” rating and issued a GBX 1,725 ($21.88) target price on shares of GSK in a research note on Tuesday, May 7th. Citigroup restated a “buy” rating and issued a GBX 2,100 ($26.64) target price on shares of GSK in a research note on Monday, June 24th. Shore Capital restated a “buy” rating on shares of GSK in a research note on Wednesday, June 12th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,950 ($24.74) price target on shares of GSK in a research note on Tuesday, June 18th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, GSK has an average rating of “Moderate Buy” and an average target price of GBX 1,791.25 ($22.72).

GSK Stock Performance

Shares of LON GSK opened at GBX 1,529.50 ($19.40) on Thursday. The business’s 50-day moving average price is GBX 1,685.84 and its two-hundred day moving average price is GBX 1,629.79. The company has a debt-to-equity ratio of 134.34, a current ratio of 0.87 and a quick ratio of 0.73. GSK has a one year low of GBX 1,302.60 ($16.52) and a one year high of GBX 1,823.50 ($23.13). The company has a market capitalization of £62.40 billion, a P/E ratio of 1,403.21, a price-to-earnings-growth ratio of 1.19 and a beta of 0.27.

Insider Buying and Selling at GSK

In other news, insider Wendy Becker purchased 446 shares of the business’s stock in a transaction on Thursday, June 20th. The stock was purchased at an average price of GBX 1,614 ($20.47) per share, with a total value of £7,198.44 ($9,131.60). Insiders own 1.60% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.